REGENXBIO Stock Forecast, Price & News

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO or view top-rated stocks.

How has REGENXBIO's stock price been impacted by COVID-19?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has decreased by 2.8% and is now trading at $31.96.
View which stocks have been most impacted by COVID-19.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for REGENXBIO.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.50. REGENXBIO had a negative trailing twelve-month return on equity of 44.70% and a negative net margin of 228.08%. During the same quarter last year, the business posted $0.23 EPS.
View REGENXBIO's earnings history.

What price target have analysts set for RGNX?

8 analysts have issued 1-year price objectives for REGENXBIO's stock. Their forecasts range from $17.00 to $90.00. On average, they expect REGENXBIO's share price to reach $58.25 in the next twelve months. This suggests a possible upside of 82.3% from the stock's current price.
View analysts' price targets for REGENXBIO or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:

• Kenneth T. Mills, President, Chief Executive Officer & Director
• Curran M. Simpson, SVP, Chief Operations & Technology Officer
• Vit Vasista, Chief Financial Officer & Senior Vice President
• Olivier Danos, Chief Scientific Officer & Senior Vice President
• Stephen Pakola, Chief Medical Officer & Senior Vice President

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Who are some of REGENXBIO's key competitors?

Some companies that are related to REGENXBIO include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Exelixis (EXEL), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Adagio Therapeutics (ADGI), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Recursion Pharmaceuticals (RXRX), SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA) and Relay Therapeutics (RLAY).
View all of RGNX's competitors.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.87%), RTW Investments LP (4.31%), Dimensional Fund Advisors LP (1.56%), Geode Capital Management LLC (1.56%), First Manhattan Co. (1.33%) and Goldman Sachs Group Inc. (0.88%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO.

Which institutional investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Carmignac Gestion, Invesco Ltd., Millennium Management LLC, Morgan Stanley, WS Management Lllp, South Dakota Investment Council, and Russell Investments Group Ltd.. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Curran Simpson, Kenneth T Mills, Patrick J Christmas, Vittal Vasista, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO or view top insider-selling stocks.

Which institutional investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, First Manhattan Co., BlackRock Inc., Assenagon Asset Management S.A., Two Sigma Investments LP, Voloridge Investment Management LLC, RTW Investments LP, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for REGENXBIO or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $31.96.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.37 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111.25 million in net income (profit) each year or ($5.17) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

Where are REGENXBIO's headquarters?

REGENXBIO is headquartered at 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].